China SXT Pharmaceuticals
SXTC
3 hedge funds and large institutions have $133K invested in China SXT Pharmaceuticals in 2025 Q2 according to their latest regulatory filings, with 2 funds opening new positions, 1 increasing their positions, reducing their positions, and 0 closing their positions.
908% more capital invested
Capital invested by funds: $13.1K → $133K (+$119K)
200% more funds holding
Funds holding: 1 → 3 (+2)
0% more ownership
Funds ownership: 0% → 0% (+0%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UBS Group
Zurich,
Switzerland
|
+$109K |
| 2 |
VF
Virtu Financial
New York
|
+$26.4K |
| 3 |
TRCT
Tower Research Capital (TRC)
New York
|
+$284 |
Top Sellers
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
1
UBS Group
Zurich,
Switzerland
| $108K | +$109K | +382 | +1,091% |
|
|
VF
2
Virtu Financial
New York
| $24K | +$26.4K | +93 | New |
|
|
TRCT
3
Tower Research Capital (TRC)
New York
| $261 | +$284 | +1 | New |
|
SXTC Hedge Fund Activity: Q2 2025 in Review
3 of the 7,598 institutional investors tracked by Wall St. Rank reported a position in China SXT Pharmaceuticals (SXTC) for Q2 2025, worth a combined $133K — up 908% from $13.1K a quarter earlier.
Buyers outnumbered sellers: 2 funds opened new SXTC positions and 0 closed out — a net gain of 2 holders — while 1 added to existing stakes and 0 trimmed.
The largest buyer was UBS Group, adding an estimated $109K.
- 3 institutional investors held China SXT Pharmaceuticals (SXTC) as of Q2 2025, up from 1 in Q1 2025.
- Funds reported $133K of China SXT Pharmaceuticals stock for Q2 2025, up 908% quarter-over-quarter.
- 2 funds opened new China SXT Pharmaceuticals positions in Q2 2025 and 0 closed out, a net change of +2 holders.
- The largest China SXT Pharmaceuticals buyer in Q2 2025 was UBS Group, an estimated $109K added.
Based on aggregated 13F filings for Q2 2025.